A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) worked better than standard Sutent (sunitinib) at delaying disease progression and prolonging survival in adults with untreated advanced renal cell carcinoma (RCC) — the most common type of kidney cancer in adults — according to data from a Phase 3 clinical trial. In addition, Lenvima also outperformed…
Enhertu (trastuzumab deruxtecan) has been granted conditional approval in the U.K. for the treatment of adults with inoperable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens. A conditional approval is given to therapies whose benefit of immediate availability outweighs the risk of having less comprehensive data. Still, regulators require additional…
To meet a U.S. goal to effectively treat and prevent Alzheimer’s disease by 2025, patient, caregiver, and advocacy communities are recommending a $289 million hike in federal research dollars for fiscal year 2022. UsAgainstAlzheimer’s is supporting that recommendation — and calling for greater urgency in meeting national Alzheimer’s community goals set nearly a decade ago.…
People with advanced multiple myeloma and diffuse large B-cell lymphoma (DLBCL) will soon be able to access Xpovio (selinexor) outside the U.S. through a managed access program. This program, also known as a named patient program, allows patients and doctors in countries where a medicine is not yet approved or available access to them, provided the medicine…
C4 Therapeutics is preparing to launch a clinical trial testing its lead investigational therapy CFT7455 in multiple myeloma and other blood cancers. The U.S. Food and Drug Administration (FDA) approved the company’s application requesting a Phase 1/2a trial, which could open by mid-year. “With FDA clearance achieved, we are on track to advance CFT7455 into…
Treatment with Opdivo (nivolumab) after surgery significantly delays disease recurrence or death in patients with muscle-invasive urothelial carcinoma, a form of bladder cancer that has spread to nearby muscles, according to data from a Phase 3 clinical trial. These beneficial effects were seen in the overall population of patients in the CheckMate-274 trial (NCT02632409), as…
Combining Erleada (apalutamide) and Zytiga (abiraterone acetate) to treat metastatic castration-resistant prostate cancer (mCRPC) significantly extends the time patients live without signs of disease worsening, compared with Zytiga alone, Janssen announced in a press release. Findings from the ACIS Phase 3 trial (NCT02257736), which enrolled patients on androgen deprivation therapy (ADT) who had not been treated with…
The hormone progesterone helps to drive the development of metastatic ovarian cancer, and blocking progesterone signaling may be a useful strategy for preventing the cancer, a study in mice suggests. The study, “Targeting progesterone signaling prevents metastatic ovarian cancer,” was published in PNAS. High-grade serous carcinoma (HGSC) is the most common, and most deadly, form of…
An open-label Phase 2 clinical trial will test the safety and efficacy of IRX-2, an experimental immunology-based cancer therapy, in combination with Keytruda (pembrolizumab) and chemotherapy. The study is enrolling adults with triple-negative breast cancer (TNBC) — cancers not driven by the hormones progesterone or estrogen, or by the protein HER2 — according to the…
A virtual celebrity-studded HFC event aimed at caregivers for Alzheimer’s disease and dementia patients is on tap for Friday, National Caregivers Day. Called HFC CareCon and presented by Kensington Senior Living in both English and Spanish, the free two-hour event will be hosted by HFC co-founder and actor Lauren Miller Rogen, with a special appearance from…
